The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Xerostomia Therapeutics Global Market Report 2023, the xerostomia therapeutics market is expected to show significant growth in the forecast period.

Strong Market Growth in Recent Years

• Market Size Growth: The xerostomia therapeutics market has seen significant growth, increasing from $2.04 billion in 2023 to $2.14 billion in 2024, reflecting a 5.3% CAGR.
• Key Drivers: This growth is driven by rising incidences of xerostomia among the elderly, advancements in product development, greater awareness of xerostomia-related products, and an increase in chronic medical conditions.

Projected Market Expansion by 2028

• Future Projections: The market is expected to grow further, reaching $2.65 billion by 2028, with a CAGR of 5.4%.
• Growth Factors: Contributing factors include the availability of cost-effective medications, increased oral health awareness, government initiatives, and a rise in medication usage.

Chemotherapy’s Role in Market Expansion

• Chemotherapy Impact: The growing use of chemotherapy in cancer treatment is a significant driver of the xerostomia therapeutics market.
• Rising Demand: As chemotherapy becomes more widely accepted for its effectiveness in targeting cancer cells, the demand for xerostomia therapeutics, such as saliva-stimulating medications, has increased.
• Cancer Survivors: With an estimated 18.1 million cancer survivors in the U.S. in 2022, expected to grow to 22.5 million by 2032, the need for effective xerostomia treatments is likely to rise.

View More On The Xerostomia Therapeutics Market Report 2024 –
https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Innovations in Xerostomia Therapeutics

• Saliva Substitutes: Companies are focusing on developing advanced saliva substitutes to provide relief from xerostomia by mimicking the natural composition of saliva.
• Product Example: In 2021, ICPA Health Products launched “Wet Mouth,” a saliva substitute that provides moisture and lubrication for up to four hours, aiding in oral health and comfort.

Strategic Acquisitions in the Market

• Eagle Pharmaceuticals: In 2022, Eagle Pharmaceuticals acquired Acacia Pharma Group plc for $104 million, enhancing its position in the xerostomia therapeutics market.
• Market Positioning: This acquisition expands Eagle Pharmaceuticals’ product portfolio, R&D capabilities, and market access, potentially leading to cost savings and increased market share.

Market Segmentation

• By Type: The market is segmented into artificial saliva or saliva substitutes and salivary stimulants.
• By Distribution Channel: Key channels include hospital pharmacies, retail pharmacies, drug stores, mail order pharmacies, and hypermarkets/supermarkets.
• By End-User: The market serves both adult and pediatric patients.

Regional Insights

• North America: The largest market region in 2023.
• Asia-Pacific: Expected to be the fastest-growing region through 2028, driven by increased awareness and healthcare advancements.

Conclusion
The xerostomia therapeutics market is poised for robust growth, driven by innovations, strategic acquisitions, and rising demand due to the increasing prevalence of xerostomia-related conditions. With major players investing in new products and technologies, the market is set to expand significantly in the coming years.

Request A Sample Of The Global Xerostomia Therapeutics Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15700&type=smp